| |
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency.
|
|
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now.
|
|
| By Andrea Park,Nick Paul Taylor According to Evaluate’s forecasts, the biggest potential drug launches of the coming year stand to generate a collective $29 billion in annual sales by the end of the decade, nearly double the estimate for last year’s top 10. |
|
|
|
By Darren Incorvaia Just days after President Trump imposed broad restrictions on communications, meetings, travel and public appearances at the Department of Health and Human Services (HHS), the National Institutes of Health (NIH) is clarifying the extent of the freeze’s effect. |
By Andrea Park Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch with a new commercial leader. |
By Gabrielle Masson After what many considered a “slow” year for initial public offerings, January has ushered in a string of biotechs filing to go public. But 2024 wasn’t slow—it was actually quite normal. |
|
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now.
|
|
By Angus Liu Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them as new standard treatments for certain colorectal cancer patients. |
By Fraiser Kansteiner While Fujifilm Diosynth Biotechnologies isn’t immune to the challenges facing the broader CDMO industry, the company’s long-running expansion journey—and its ability to snare high-profile pharma clients—has blunted many of the pressures met by its peers. |
By Conor Hale The FDA has tapped Sara Brenner to serve as acting commissioner as it awaits new leadership from the Trump administration to complete the congressional confirmation process. |
By Darren Incorvaia Demand slipped for several large contract research organizations last year, and a new report from William Blair suggests these firms shouldn’t expect much improvement in 2025. |
By Kevin Dunleavy For "ethical" reasons, Merck has halted the phase 3 HYPERION trial of its pulmonary arterial hypertension (PAH) treatment Winrevair after reviewing positive interim results from another study and evaluating the drug’s overall clinical program. All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said. |
By Darren Incorvaia British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work with the University of Oxford on cancer vaccines. |
By Zoey Becker The German manufacturer is ending operations at its Stevenage, U.K., site after a shortfall in demand for cell and gene therapy services prompted the firm to focus more on biologics. |
Fierce podcastsDon’t miss an episode |
| | While major payers skipped out on this year’s event, health tech companies, health systems and insurtechs all made appearances to share their latest updates with investors. |
|
|---|
|
|
| ResearchStudy shows significant Rx growth using new EHR marketing technique. Sponsored by: Veradigm |
| WhitepaperHow can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| ResearchRead this case study to discover how programmatic EHR advertising can transform your omnichannel marketing strategy. Sponsored by: Veradigm |
| |
|
